Biobanking at UCL
Why is Biobanking important?
The main aim of developing Biobanking at UCL is to maximise the value of data and biospecimen repositories across all campuses. Biobanking is now heavily relied upon Worldwide for advancing research into a comprehensive variety of health problems and to develop new ideas, technology and knowledge. Access to biorepositories and associated data is crucial to ongoing biomedical research. In order for large sample collections and data to be fully appreciated, ensuring the robust, accurate management of tissue and data repositories is vital. By combining the resources already available at UCL in a rationalized model, the full potential of these sample and data sets in the development of new translational research ideas and advancement of personalised medicine can be realised, not only by those at UCL but by the wider research community.
Developing infrastructure for Biobanking at UCL will help maximise, for patient benefit, the value of data and biospecimen repositories across all campuses. Patients’ samples with pseudoanonymised data are crucial for the development of biomedical research, particularly translational research.
There are nine HTA-licenced Biobanks within UCL. These include:
- HTA Licence 11016 - Royal Free Hospital
- HTA Licence 12055 - UCL Cancer Institute
- HTA Licence 12120 - UCL Anatomy Licence
- HTA Licence 12161 - UCL Ear Institute
- HTA Licence 12177 - UCL Institute of Ophthalmology
- HTA Licence 12198 - UCL Institute of Neurology
- HTA Licence 12220 - UCL Institute of Child Health
- HTA Licence 12277 - UCL Eastman Dental Institute
- HTA Licence 12620 - UCL Pathology Collections and Public Display
Page last modified on 07 aug 15 15:25